ILMN Add to watchlist
$132.26 +1.94 (+1.49%)
After Hours: $132.26 +0.00 (+0.00%)
Last updated: Apr 15, 2026 22:47
52-Week Range
$132.26
$69.83 $132.26 $155.53

Fundamentals Overview

Illumina, Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 24 PEG 0.14 P/B 7.43 P/S 4.66

Profitability

Net margin 19.6%

Risk (Beta)

1.49 — higher vol

Earnings & growth

EPS $5.52 Rev +7% Profit +122.7% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 60% confidence Risk: High Volatility — Beta 1.49. Consider smaller position size due to higher beta.

Supporting (Buy):

Analyst grade: B+

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -9.8% · Beta 1.49 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$20.22B
P/E (TTM)
23.96
EPS (TTM)
$5.52
Dividend Yield
N/A
52-Week Range
$69.83 - $155.53
Volume vs Avg
N/A
Beta
1.49

About

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and dev...
Sector: Healthcare
Headquarters: US
Employees: 8,970
IPO Date: Jul 2000
Beta: 1.49 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 3, Equal Weight: 1, Hold: 6, Neutral: 8, Outperform: 4, Overweight: 1, Sector Perform: 1, Sell: 1, Underweight: 5.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-60.74; current price is $132.26. That’s a -145.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 23.96
PEG (TTM) 0.14
P/B (TTM) 7.43
P/S (TTM) 4.66
P/FCF (TTM) 21.54
Liquidity & enterprise
Current Ratio (TTM) 2.08
Quick Ratio (TTM) 1.72
Cash Ratio (TTM) 0.89
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 19.58%
Gross margin (TTM) 66.49%
Operating margin (TTM) 19.92%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ILMN.

Analyst Sentiment at a Glance

B+ Sentiment Weakening
Buy 3Equal Weight 1Hold 6Neutral 8Outperform 4Overweight 1Sector Perform 1Sell 1Underweight 5
0 upgrades, 2 downgrades
Price Target Consensus
Current $132.26
Median $150.00
Consensus $147.13
Low consensus $110.00
High consensus $170.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Piper Sandler maintain Overweight Overweight 2026-02-09
JP Morgan maintain Neutral Neutral 2026-02-06
Canaccord Genuity maintain Hold Hold 2026-01-26
Guggenheim maintain Buy Buy 2026-01-26
Stifel maintain Buy Buy 2026-01-20
TD Cowen maintain Hold Hold 2026-01-07
Guggenheim maintain Buy Buy 2026-01-05
Canaccord Genuity maintain Hold Hold 2025-12-22
JP Morgan maintain Neutral Neutral 2025-12-15
Barclays maintain Underweight Underweight 2025-12-15
Baird maintain Neutral Neutral 2025-10-31
Evercore ISI Group maintain Outperform Outperform 2025-10-31
UBS maintain Neutral Neutral 2025-10-31
Barclays maintain Underweight Underweight 2025-10-31
Canaccord Genuity maintain Hold Hold 2025-10-31
JP Morgan maintain Neutral Neutral 2025-10-31
TD Cowen maintain Hold Hold 2025-10-31
Evercore ISI Group maintain Outperform Outperform 2025-10-07
Barclays maintain Underweight Underweight 2025-10-02
Morgan Stanley maintain Equal Weight Equal Weight 2025-08-04
Barclays maintain Underweight Underweight 2025-08-01
RBC Capital maintain Outperform Outperform 2025-08-01
UBS maintain Neutral Neutral 2025-08-01
JP Morgan maintain Neutral Neutral 2025-08-01
Canaccord Genuity maintain Hold Hold 2025-08-01
Baird maintain Neutral Neutral 2025-07-28
Scotiabank downgrade Sector Outperform Sector Perform 2025-07-11
Citigroup downgrade Neutral Sell 2025-07-09
Evercore ISI Group maintain Outperform Outperform 2025-07-08
Barclays maintain Underweight Underweight 2025-06-24